Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate
Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate
Orchestra BioMed Hldgs第一季度每股收益美元（0.38美元）超过预期（0.41美元），销售额为62万美元，低于预期的940.00万美元
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $620.00 thousand which missed the analyst consensus estimate of $940.00 thousand by 34.04 percent. This is a 46.74 percent decrease over sales of $1.16 million the same period last year.
Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）公布的季度亏损为每股0.38美元，比分析师普遍预期的0.41美元（0.41美元）高出7.32％。这比去年同期每股亏损0.40美元（0.40）增长了5％。该公司公布的季度销售额为62万美元，比分析师普遍预期的94万美元低34.04％。这比去年同期的116万美元销售额下降了46.74％。